- cafead Jul 12, 2021 at 10:42: AM
via Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year.
The deal will see Novo pay $100 million in upfront and near-term fees for worldwide rights to the phase 2-ready anti-amyloid immunotherapy PRX004.
article source
The deal will see Novo pay $100 million in upfront and near-term fees for worldwide rights to the phase 2-ready anti-amyloid immunotherapy PRX004.
article source